査読付原著論文
総説
投稿中論文

査読付原著論文

Peer-reviewed English Original Articles

2024年

  1. Fukushima H, Takao S, Furusawa A, Valera Romero V, Gurram S, Kato T, Okuyama
    S, Kano M, Choyke PL, Kobayashi H.
    Theranostic near-infrared photoimmunotherapy targeting Nectin-4 in bladder cancer
    preclinical models.
    Cancer Letters 2024; 585:216606.
  2. Kobayashi T, Noma K, Kato T, Nishiwaki N, Ohara T, Nishimura S, Kunitomo T,
    Kawasaki K, Akai M, Komoto S, Kashima H, Kikuchi S, Tazawa H, Shirakawa Y, Choyke
    PL, Kobayashi H, Fujiwara T.
    Near-infrared Photoimmunotherapy Targeting Cancer-Associated Fibroblasts in PatientDerived Xenograft models using a Humanized anti-Fibroblast Activation Protein Antibody

    Molecular Cancer Therapeutics 2024;23(7):1031-1042.

  3. Fukushima H, Furusawa A, Takao S, Matikonda SS, Kano M, Okuyama S, Yamamoto H, Choyke PL, Schnermann MJ, Kobayashi H.

    Phototruncation cell tracking with near-infrared photoimmunotherapy using heptamethine cyanine dye to visualize migratory dynamics of immune cells.
    eBioMedicine 2024;102:105050.

  4. Akai M, Noma K, Kato T, Nishimura S, Matsumoto H, Kawasaki K, Kunimoto T, Kobayashi T, Nishiwaki N, Kashima H, Kikuchi S, Ohara T, Tazawa H, Choyke PL, Kobayashi H, Fujiwara T.
    Fibroblast Activation Protein-targeted Near-Infrared Photoimmunotherapy Selectively Depletes Immunosuppressive Cancer-Associated Fibroblasts and Remodels Local Tumor Immunity.
    British Journal of Cancer 2024;130(10):1647-1658.

  5. Inagaki FF, Kano M, Furusawa A, Kato T, Okada R, Fukushima H, Takao S, Okuyama S, Choyke PL, Kobayashi H.
    Near-infrared photoimmunotherapy targeting PD-L1: Improved efficacy by pre-conditioning the tumor microenvironment.
    Cancer Science 2024;115(7):2396-2409.

  6.  Jin J, Barnett JD, Mironchik Y, Gross J, Kobayashi H, Levin A, Bhujwalla ZM.
    Photoimmunotheranostics of epithelioid sarcoma by targeting CD44 or EGFR.
    Translational Oncology 2024;45 :101966.

  7. Suzuki M, Hara D, Kobayashi H, Hanaoka H.
    Elimination of radiation-induced senescent cells by near-infrared photoimmunotherapy.
    Cancer Medicine 2024 ;13(12):e7381.

  8. Fukushima H, Furusawa A, Takao S, Thankarajan E, Luciano MP, Usama SM, Kano M, Okuyama S, Yamamoto H, Suzuki M, Kano M, Choyke PL, Schnermann MJ, Kobayashi H.
    Near-infrared duocarmycin photorelease from a Treg-targeted antibody-drug conjugate improves efficacy of PD-1 blockade in syngeneic murine tumor models
    Oncoimmunology 2024 ;13(1):2370544.

  9. Fukushima H, Takao S, Furusawa A, Suzuki M, Yang Y, Ricketts CJ, Kano M, Okuyama S, Yamamoto H, Kano M, Ball MW, Choyke PL, Linehan M, Kobayashi H.
    Carbonic anhydrase-9-targeted near-infrared photoimmunotherapy as a theranostic modality for clear cell renal cell carcinoma.
    Molecular Cancer Therapeutics 2024 (in press)

  10. Motofumi Suzuki,Hisataka Kobayashi, Hirofumi Hanaoka.
    Evaluation of a Novel Lateral Emitting Laser Fiber for Near-Infrared Photoimmunotherapy.
    Cansers(Basel).2024 Jul 17;16(14):2558.

2023年

  1.  Inagaki FF, Wakiyama H, Furusawa A, Okada R, Kato T, Fujimura D, Okuyama S,
    Fukushima H, Takao S, Choyke PL, Kobayashi H.
    Near-infrared photoimmunotherapy (NIR-PIT) of bone metastases in an animal model.
    Biomedicine & Pharmacotherapy 2023 ;160:114390. doi: 10.1016/j.biopha.2023.114390.
  2. Kato T, Riahin C, Furusawa A, Fukushima H, Wakiyama H, Okuyama S, Takao S,
    Choyke PL, Ptaszek M, Rosenzweig Z, Kobayashi H.
    Simultaneous Multicolor Imaging of Lymph Node Chains using Hydroporphyrin-Doped
    Near-Infrared-Emitting Polymer Dots.
    Nanomedicine (London) 2023; 18(8):659-666
  3. Iwase T, Ito K, Nishimura T, Miyakawa K, Ryo A, Kobayashi H, Mitsunaga M.
    Photoimmunotechnology as a powerful biological tool for molecular-based elimination of
    target microbes and cells.
    Nature Protocol 2023;18(11):3390-3412.
  4. Fukushima H, Furusawa A, Kato T, Wakiyama H, Takao S, Okuyama S, Choyke PL,
    Kobayashi H.
    Intratumoral interleukin-15 improves efficacy of near-infrared photoimmunotherapy.
    Molecular Cancer Therapeutics 2023; 22(10):1215-1227.
  5. Takao S, Fukushima H, King AP, Kato T, Furusawa A, Okuyama S, Kano M, Choyke
    PL, Escorcia FE, Kobayashi H.
    Near-infrared Photoimmunotherapy in a Model of Hepatocellular Carcinoma using
    Cetuximab-IR700.
    Cancer Science 2023; In press.
  6. Miyazaki NL, Furusawa A, Choyke PL, Kobayashi H.
    Review of RM-1929 near infrared photoimmunotherapy clinical efficacy for unresectable
    and/or recurrent head and neck squamous cell carcinoma.
    Cancers 2023; 15(21): 5117.
  7. Kato T, Furusawa A, Okada R, Inagaki F, Wakiyama H, Furumoto H, Fukushima H,
    Okuyama S, Choyke PL, Kobayashi H.
    Near-infrared photoimmunotherapy targeting podoplanin-expressing cancer cells and
    cancer-associated fibroblasts
    Molecular Cancer Therapeutics 2023 Jan 3;22(1):75-88. doi: 10.1158/1535-7163.MCT-22-
    0313.

2022年

  1. Okada R, Kato T, Furusawa A, Inagaki F, Wakiyama H, Fujimura D, Okuyama S,
    Furumoto H, Fukushima H, Choyke PL, Kobayashi H.
    Selection of antibody and light exposure regimens alters therapeutic effects of EGFRtargeted near-infrared photoimmunotherapy.
    Cancer Immunology Immunotherapy 2022 ;71(8):1877-1887. doi: 10.1007/s00262-021-
    03124-x.
  2. Furusawa A, Okada R, Inagaki F, Wakiyama H, Kato T, Choyke PL, Kobayashi H
    CD29 targeted near-infrared photoimmunotherapy (NIR-PIT) in the treatment of a
    pigmented melanoma model
    Oncoimmunology 2022 ;11(1):2019922. doi: 10.1080/2162402X.2021.2019922
  3. Jin J, Krishnamachary B, Mironchik Y, Sivakumar I, Wildes F, Barnett JD, Hung C-F,
    Nimmagadda S, Kobayashi H, Bhujwalla ZM, Penet M-F.
    PD-L1 Near Infrared Photoimmunotherapy of Ovarian Cancer Model
    Cancers 2022 ;14(3):619. doi: 10.3390/cancers14030619.
  4. Tazawa H, Shigeyasu K, Noma K, Kagawa S, Kobayashi H, Imamura T, Fujiwara T.
    Tumor-targeted fluorescence imaging systems for diagnosis and treatment of cancer.
    Cancer Science 2022 ;113(6):1919-1929. doi: 10.1111/cas.15369.
  5. Wakiyama H, Furusawa A, Okada R, Inagaki F, Kato T, Furumoto H, Fukushima H,
    Okuyama S, Choyke PL, Kobayashi H.
    Opening up new VISTAs: V-domain Immunoglobulin Suppressor of T cell Activation
    (VISTA) targeted near-infrared photoimmunotherapy (NIR-PIT) for enhancing host
    immunity against cancers.
    Cancer Immunology Immunotherapy 2022 ;71(12):2869-2879. doi: 10.1007/s00262-022-
    03205-5.
  6. . Moriya T, Hashimoto M, Matsushita H, Masuyama S, Yoshida R, Okada R, Furusawa
    A, Fujimura D, Wakiyama H, Kato T, Choyke PL, Kusumoto Y, Chtanova T, Kobayashi
    H, Tomura M.
    Near-infrared photoimmunotherapy induced tumor cell death enhances tumor dendritic cell
    migration.
    Cancer Immunology Immunotherapy 2022 ;71(12):3099-3106. doi: 10.1007/s00262-022-
    03216-2.
  7. Fukushima H, Matikonda SS, Usama SM, Furusawa A, Kato T, Štacková L, Klán P,
    Kobayashi H, Schnermann MJ.
    Cell labeling with spatiotemporal control using cyanine phototruncation
    2
    Journal of the American Chemical Society 2022 ;144(25):11075-11080. doi:
    10.1021/jacs.2c02962.
  8. Fukushima H, Kato T, Furusawa A, Okada R, Wakiyama H, Furumoto H, Okuyama S,
    Kondo E, Choyke PL, Kobayashi H.
    Intercellular adhesion molecule-1 (ICAM-1)-targeted near-infrared photoimmunotherapy in
    the treatment of triple-negative breast cancer.
    Cancer Science 2022 ;113(9):3180-3192. doi: 10.1111/cas.15466.
  9. Kato T, Okada R, Furusawa A, Wakiyama H, Furumoto H, Fukushima H, Okuyama S,
    Choyke PL, Kobayashi H.
    A comparison of the effectiveness of IgG antibody vs. F(ab’)2 antibody fragment in
    CTLA4-targeted near-infrared photoimmunotherapy
    Molecular Pharmaceutics 2022 ;19(10):3600-3611. doi:
    10.1021/acs.molpharmaceut.2c00242.
  10. Mitsunaga M, Ito K, Nishimura T, Miyata H, Miyakawa K, Morita T, Ryo A,
    Kobayashi H, Mizunoe Y, Iwase T.
    Evidence of a targeted antimicrobial therapeutic strategy against different bacterial, fungal,
    and viral pathogens.
    Commission Biology 2022 ;5(1):647. doi: 10.1038/s42003-022-03586-4.
  11. Takahashi K, Yasui H, Taki S, Shimizu M, Koike C, Taki K, Hiroshi Y, Baba Y,
    Kobayashi H, Sato K.
    Near-infrared-induced drug release from antibody-drug double conjugates exerts a
    cytotoxic photo-bystander effect.
    Bioengineering and Translational Medicine 2022 ;7(3):e10388. doi: 10.1002/btm2.10388.
  12. Barnett JD, Jin J, Penet M-F, Kobayashi H, Bhujwalla ZM.
    Phototheranostics of splenic myeloid-derived suppressor cells and its impact on spleen
    metabolism in tumor-bearing mice.
    Cancers 2022;14(15):3578. doi: 10.3390/cancers14153578.
  13. Furumoto H, Okada R, Kato T, Wakiyama H, Inagaki F, Fukushima H, Okuyama S,
    Furusawa A, Choyke PL, Kobayashi H.
    Optimal light dose for hEGFR-targeted near-infrared photoimmunotherapy.
    Cancers 2022;14(16):4042. doi: 10.3390/cancers14164042.
  14.  Jin J, Barnett JD, Krishnamachary B, Mironchik Y, Luo C, Kobayashi H, Bhujwalla
    ZM.
    Targeting cancer associated fibroblasts by photoimmunotheranostics of fibroblast activation
    protein-α
    Cancer Science 2022 2023 Jan;114(1):236-246. doi: 10.1111/cas.15601.
  15. Inagaki FF, Kato T, Furusawa A, Okada R, Wakiyama H, Furumoto H, Okuyama S,
    Choyke PL, Kobayashi H.
    Disialoganglioside GD2-targeted near-infrared photoimmunotherapy (NIR-PIT) in tumors
    of neuroectodermal origin.
    Pharmaceutics 2022 ;14(10):2037. doi: 10.3390/pharmaceutics14102037.
  16. Wakiyama H, Furusawa A, Okada R, Inagaki F, Kato T, Furumoto H, Fukushima H,
    Okuyama S, Choyke PL, Kobayashi H.
    Treg-dominant tumor microenvironment is responsible for hyperprogressive disease after
    PD-1 blockade therapy
    Cancer Immunology Research 2022 ;10(11):1386-1397. doi: 10.1158/2326-6066.CIR-22-
    0041.
  17. Sato H, Noma K, Ohara T, Kawasaki K, Akai M, Kobayashi T, Nishiwaki N,
    Narusaka T, Komoto S, Kashima H, Katsura Y, Kato T, Kikuchi S, Tazawa H, Kagawa S,
    Shirakawa Y, Kobayashi H, Fujiwara T.
    Dual-targeted near-infrared photoimmunotherapy for esophageal cancer and cancerassociated fibroblasts in the tumor microenvironment.
    Scientific Reports 2022 ;12(1):20152. doi: 10.1038/s41598-022-24313-3.
  18. Kato T, Fukushima H, Furusawa A, Okada R, Wakiyama H, Furumoto H, Okuyama S,
    Takao S, Choyke PL, Kobayashi H.
    Selective depletion of polymorphonuclear myeloid derived suppressor cells in tumor beds
    with near infrared photoimmunotherapy enhances host immune response.
    OncoImmunology 2022 ;11(1):2152248. doi: 10.1080/2162402X.2022.2152248